STOCK TITAN

Rockwell Medical to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI), a global healthcare company specializing in hemodialysis products, has announced its participation in the H.C. Wainwright 3rd Annual Kidney Virtual Conference. The company's President and CEO, Dr. Mark Strobeck, will be presenting at this virtual event.

Investors and interested parties can access the webcast of Rockwell Medical's presentation through the company's 'Investors' page at IR.RockwellMed.com. The webcast will remain available for 30 days following the conference. For more information about the conference, visit hcwevents.com/kidneyconference.

This presentation provides an opportunity for Rockwell Medical to showcase its portfolio of hemodialysis products and discuss its strategies in the kidney care market.

Positive
  • None.
Negative
  • None.

WIXOM, Mich.--(BUSINESS WIRE)-- Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck, will present at the H.C. Wainwright 3rd Annual Kidney Conference, which is being held today virtually. For more information, visit hcwevents.com/kidneyconference.

A webcast of Rockwell Medical's presentation can be accessed through the Company's "Investors" page at IR.RockwellMed.com and will be available for 30 days following the conference.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at freestanding outpatient dialysis centers, at hospital-based outpatient centers, at skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the largest supplier of liquid bicarbonate concentrates and the second largest supplier of acid and dry bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of all hemodialysis concentrates. Certified as a Great Place to Work® in 2023 and 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.RockwellMed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” “aim to,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Heather R. Hunter

SVP, Chief Corporate Affairs Officer

(248) 432-1362

IR@RockwellMed.com

Source: Rockwell Medical, Inc.

FAQ

When is Rockwell Medical (RMTI) presenting at the H.C. Wainwright Kidney Conference?

Rockwell Medical (RMTI) is presenting at the H.C. Wainwright 3rd Annual Kidney Virtual Conference today. The exact date is not specified in the press release.

Who is presenting for Rockwell Medical (RMTI) at the H.C. Wainwright Kidney Conference?

Dr. Mark Strobeck, the President and Chief Executive Officer of Rockwell Medical (RMTI), will be presenting at the H.C. Wainwright 3rd Annual Kidney Virtual Conference.

How can I access Rockwell Medical's (RMTI) presentation at the H.C. Wainwright Kidney Conference?

You can access the webcast of Rockwell Medical's (RMTI) presentation through the company's 'Investors' page at IR.RockwellMed.com. The webcast will be available for 30 days following the conference.

What products does Rockwell Medical (RMTI) develop and manufacture?

Rockwell Medical (RMTI) develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide.

Rockwell Medical, Inc. (DE)

NASDAQ:RMTI

RMTI Rankings

RMTI Latest News

RMTI Stock Data

78.66M
31.03M
12.33%
21.27%
2.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WIXOM